Maintenance therapy in HER2-positive mBC is evolving from a treatment break into a strategic intensification.
Data from PATINA and HER2CLIMB-05 show that adding targeted agents—like CDK4/6 inhibitors or tucatinib—to the standard dual blockade can significantly extend disease control. This clip explores how biology now dictates the maintenance strategy to maximize the 1st line window.
PATINA, HER2CLIMB-05 & the Maintenance Therapy Debate
You may also like
Recommended Videos
